NuVasive Past Earnings Performance
Past criteria checks 1/6
NuVasive's earnings have been declining at an average annual rate of -33%, while the Medical Equipment industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 2.1% per year. NuVasive's return on equity is 3.2%, and it has net margins of 2.3%.
Key information
-33.0%
Earnings growth rate
-33.2%
EPS growth rate
| Medical Equipment Industry Growth | 8.9% |
| Revenue growth rate | 2.1% |
| Return on equity | 3.2% |
| Net Margin | 2.3% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?
Apr 18
What Does NuVasive, Inc.'s (NASDAQ:NUVA) Share Price Indicate?
Jan 24NuVasive, Inc.'s (NASDAQ:NUVA) Intrinsic Value Is Potentially 48% Above Its Share Price
Dec 31Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal
Dec 05These 4 Measures Indicate That NuVasive (NASDAQ:NUVA) Is Using Debt Reasonably Well
Nov 13Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)
Sep 22Capital Allocation Trends At NuVasive (NASDAQ:NUVA) Aren't Ideal
Sep 01NuVasive Likely Undervalued, But It's Hard To Find Catalysts
Aug 17Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?
Aug 11NuVasive Non-GAAP EPS of $0.47 misses by $0.09, revenue of $310.5M beats by $4.12M
Aug 03NuVasive: Industry Tailwinds More Than Fairly Priced
Jun 13Calculating The Intrinsic Value Of NuVasive, Inc. (NASDAQ:NUVA)
Jun 01Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital
May 11NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet
Apr 20At US$56.32, Is NuVasive, Inc. (NASDAQ:NUVA) Worth Looking At Closely?
Mar 30NuVasive's Turnaround Story Needs A Boost From Better Results
Mar 01Investors Could Be Concerned With NuVasive's (NASDAQ:NUVA) Returns On Capital
Dec 28Should You Think About Buying NuVasive, Inc. (NASDAQ:NUVA) Now?
Dec 02NuVasive (NASDAQ:NUVA) Has A Pretty Healthy Balance Sheet
Nov 11NuVasive, Inc. (NASDAQ:NUVA) Shares Could Be 32% Below Their Intrinsic Value Estimate
Oct 21Be Wary Of NuVasive (NASDAQ:NUVA) And Its Returns On Capital
Sep 29At US$59.79, Is It Time To Put NuVasive, Inc. (NASDAQ:NUVA) On Your Watch List?
Aug 18NuVasive Still Getting No Love With COVID-19 And Competitive Worries
Aug 12Does NuVasive (NASDAQ:NUVA) Have A Healthy Balance Sheet?
Jul 27Are Investors Undervaluing NuVasive, Inc. (NASDAQ:NUVA) By 21%?
Jun 17Some Investors May Be Worried About NuVasive's (NASDAQ:NUVA) Returns On Capital
May 30Why We Think NuVasive, Inc.'s (NASDAQ:NUVA) CEO Compensation Is Not Excessive At All
May 12Is NuVasive (NASDAQ:NUVA) Using Too Much Debt?
Mar 30Is Now The Time To Look At Buying NuVasive, Inc. (NASDAQ:NUVA)?
Mar 09Need To Know: NuVasive, Inc. (NASDAQ:NUVA) Insiders Have Been Buying Shares
Feb 16
A Look At The Fair Value Of NuVasive, Inc. (NASDAQ:NUVA)
Jan 26NuVasive stock gains on study results of its X360 surgery approach
Jan 06What Type Of Returns Would NuVasive's(NASDAQ:NUVA) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Jan 05Revenue & Expenses BreakdownBeta
How NuVasive makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 1,226 | 28 | 653 | 102 |
| 31 Mar 23 | 1,219 | 20 | 650 | 100 |
| 31 Dec 22 | 1,202 | 40 | 634 | 99 |
| 30 Sep 22 | 1,199 | -20 | 636 | 98 |
| 30 Jun 22 | 1,174 | -40 | 628 | 98 |
| 31 Mar 22 | 1,159 | -37 | 624 | 94 |
| 31 Dec 21 | 1,139 | -64 | 610 | 93 |
| 30 Sep 21 | 1,129 | -26 | 594 | 89 |
| 30 Jun 21 | 1,153 | 2 | 594 | 86 |
| 31 Mar 21 | 1,062 | -50 | 563 | 84 |
| 31 Dec 20 | 1,051 | -37 | 547 | 80 |
| 30 Sep 20 | 1,069 | -9 | 563 | 77 |
| 30 Jun 20 | 1,065 | -4 | 570 | 75 |
| 31 Mar 20 | 1,153 | 61 | 596 | 73 |
| 31 Dec 19 | 1,168 | 65 | 611 | 72 |
| 30 Sep 19 | 1,146 | 48 | 593 | 70 |
| 30 Jun 19 | 1,127 | 52 | 581 | 67 |
| 31 Mar 19 | 1,116 | 49 | 574 | 65 |
| 31 Dec 18 | 1,102 | 12 | 576 | 62 |
| 30 Sep 18 | 1,085 | 24 | 568 | 57 |
| 30 Jun 18 | 1,060 | 41 | 553 | 55 |
| 31 Mar 18 | 1,038 | 42 | 546 | 53 |
| 31 Dec 17 | 1,027 | 82 | 540 | 50 |
| 30 Sep 17 | 1,027 | 64 | 547 | 51 |
| 30 Jun 17 | 1,019 | 35 | 554 | 50 |
| 31 Mar 17 | 996 | 53 | 549 | 50 |
| 31 Dec 16 | 962 | 37 | 534 | 48 |
| 30 Sep 16 | 906 | 42 | 510 | 44 |
| 30 Jun 16 | 867 | 51 | 489 | 40 |
| 31 Mar 16 | 834 | 31 | 468 | 37 |
| 31 Dec 15 | 811 | 66 | 457 | 36 |
| 30 Sep 15 | 800 | 62 | 454 | 37 |
| 30 Jun 15 | 790 | 47 | 457 | 37 |
| 31 Mar 15 | 777 | 33 | 460 | 38 |
| 31 Dec 14 | 762 | -17 | 457 | 37 |
| 30 Sep 14 | 749 | -18 | 457 | 36 |
| 30 Jun 14 | 728 | -9 | 446 | 34 |
| 31 Mar 14 | 703 | -11 | 433 | 32 |
| 31 Dec 13 | 685 | 8 | 420 | 32 |
| 30 Sep 13 | 660 | -1 | 403 | 33 |
| 30 Jun 13 | 639 | -6 | 389 | 33 |
| 31 Mar 13 | 628 | 3 | 377 | 35 |
| 31 Dec 12 | 620 | 3 | 372 | 35 |
| 30 Sep 12 | 605 | -4 | 368 | 34 |
Quality Earnings: NUVA has a large one-off loss of $16.9M impacting its last 12 months of financial results to 30th June, 2023.
Growing Profit Margin: NUVA became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: NUVA's earnings have declined by 33% per year over the past 5 years.
Accelerating Growth: NUVA has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: NUVA has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.7%).
Return on Equity
High ROE: NUVA's Return on Equity (3.2%) is considered low.